ArticleClinical and translational medicine2025
USP20 competitively binds to STUB1 to enhance CTSL expression and promote epithelial-mesenchymal transition in head and neck squamous cell carcinoma.
Article in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The role of ubiquitin system in ageing-related diseases and potential therapeutic opportunities.Molecular biomedicine · 2026Review
- Article
- USP20 competitively binds to STUB1 to enhance CTSL expression and promote epithelial-mesenchymal transition in head and neck squamous cell carcinoma.Clinical and translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
rationaleMetastatic head and neck squamous cell carcinoma (mHNSCC) poses a significant threat to patient survival. Previous studies have identified cathepsin L (CTSL) as a key driver of tumourigenesis, metastasis and chemoresistance. However, the regulatory mechanisms underlying CTSL expression remain poorly understood.
methodsA specific deubiquitinase responsible for CTSL expression was identified through treatment with broad-spectrum deubiquitinase inhibitors and mass spectrometry analysis. The colocalization of CTSL and USP20 in the cytoplasm was examined using confocal microscopy. The effects of CTSL or USP20 depletion on tumour biological behaviour were evaluated through various in vitro and in vivo assays.
resultsWe identified USP20 as a specific deubiquitinase of CTSL. USP20 mediates the deubiquitination and stabilization of CTSL, thereby promoting epithelial-to-mesenchymal transition and cancer stem cell renewal, ultimately enhancing metastatic potential and chemoresistance. Notably, USP20 competes with STUB1 for CTSL binding, further driving the malignant phenotype of HNSCC. Analysis of clinical samples revealed that both CTSL and USP20 are highly expressed in metastatic HNSCC tissues, with a positive correlation between their expression levels.
conclusionsOur study reveals a novel mechanism in which USP20 competitively interacts with STUB1 to stabilize CTSL and promote tumour progression. These findings provide preclinical evidence supporting USP20 as a potential therapeutic target for overcoming metastasis and chemotherapy resistance in HNSCC. KEY POINTS: USP20 deubiquitinates and stabilizes CTSL. STUB1 promotes CTSL ubiquitination and degradation. USP20 competitively binds to CTSL in competition with STUB1. Targeting USP20 sensitizes cancer cells to cisplatin or paclitaxel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.